Detailed narrative
Q2 FY25 Financial Performance Overview
Gufic Biosciences reported a slight decline in Q2 FY25 standalone revenue to ₹204.2 crores, down 4.98% year-over-year from ₹214.9 crores in Q2 FY24. EBITDA for the quarter was ₹38.7 crores, a 2.52% decrease from ₹39.7 crores last year, though the EBITDA margin improved slightly to 18.9% from 18.47%. Profit after tax (PAT) also saw a decline to ₹21.8 crores, down 6.03% from ₹23.2 crores in the prior year, with PAT margin at 10.66%.
H1 FY25 Financial Performance Overview
For the first half of FY25, total revenue stood at ₹407 crores, a marginal decrease of 0.71% compared to ₹409.9 crores in H1 FY24. However, EBITDA for H1 FY25 increased by 4.86% to ₹79.8 crores from ₹76.1 crores in H1 FY24, with EBITDA margin improving to 18.62%. PAT for H1 FY25 was ₹42.6 crores, a 2.74% decline from ₹43.8 crores in H1 FY24, resulting in a PAT margin of 10.44%.
Indore Facility Commissioning and Strategic Outlook
The new Indore facility commenced production on October 3, 2024, marking a transformative milestone. Management indicated that revenue contribution from Indore would begin in Q3 FY25, though the 'real potential' is expected to materialize over the next 2-3 years. The short-term strategy involves transferring high-demand products from Navsari to Indore to optimize capacity, allowing Navsari to focus on export orders. Long-term, Indore is positioned for regulated markets, with EU approval targeted by the end of 2025 and US FDA action anticipated in calendar year 2026.
Challenges Impacting Revenue Stagnation
Management attributed the stagnant revenue over the past 4-5 quarters to multiple factors, including capacity constraints at the Navsari facility and significant erosion in API pricing. Specifically, 20% of the company's revenue, derived from 6-8 key molecules, experienced a 35-50% erosion due to API price volatility from China. Additionally, a conservative approach was adopted in Q1 and Q2 FY25 to manage the debtor cycle, avoiding excessive credit extension at the cost of revenue.
Divisional Performance and Pipeline Expansion
The Critical Care division continues to be a backbone, expanding its pipeline with innovative antifungal and antibacterial molecules and focusing on sepsis management through engagement with over 3,000 healthcare professionals. The Ferticare division is addressing infertility rates by expanding its recombinant hormonal product pipeline and launching specialized task forces. Aesthaderm's STUNNOX is now the second most used botulinum toxin in India, while Neurocare's Zarbot has gained acceptance among 100+ neurologists.
International Business and Contract Manufacturing
Gufic's international business is growing through regulated market registrations, having recently secured approvals in Thailand, Sri Lanka, and Lithuania, and winning a UK NHS tender. The Indore facility is expected to support further international expansions. The company is actively pursuing contract manufacturing (CMO/CDMO) opportunities, with audits by domestic and international partners ongoing since May-July, and the CMO/CDMO business expected to be initiated in November-December.
Selvax Oncology Project Update
The immune-oncology project, Selvax, targeting solid tumors, has shown promising results in animal studies, including a reported 92% cure rate out of 24 animals in expert studies. While dose determination studies are still pending, the company is working on cell line scalability and large-scale production of anti-CD40 antibodies. Management views Selvax as a 5-6 year window project, emphasizing cautious optimism until further large-scale study data is available.